Effective June 1, 2011, the Amphotec and Amphocil product line has been acquired from Kadmon by Alkopharma S.A. and Alkpoharma USA, Inc. (collectively, "Alkopharma"). All comments and questions related to Amphotec and Amphocil should be directed to the attention of Perry E. Bourkas, who can be reached at (i) US mobile: (619) 709-7947, (ii) Canadian mobile: (416) 710-7947 and (iii) e-mail: perry.bourkas@gmail.com.